Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
Part of paid clinical trials in Tucson, Arizona.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT04652726
- Phase
- PHASE3
- Status
- Completed
Conditions
- Familial Hypercholesterolemia - Heterozygous
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Inclisiran — DRUGInclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
- Placebo — DRUGSterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Study Details
This was a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C).
Key Dates
- Start date
- Jan 27, 2021
- Status verified
- Dec 2025
- Primary completion
- Nov 9, 2023
- Completion
- Nov 27, 2024
Study Design
- Enrollment
- 141 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: InclisiranYear 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
- Placebo Comparator: PlaceboYear 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
Primary Outcome Measure
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) [ Time Frame: Baseline and Day 330 ]
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Tucson Medical Center | Tucson | Arizona | 85712 | - |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | - |
| Wake Forest U of Health Sciences | Winston-Salem | North Carolina | 27157 | - |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229-3039 | - |
| Childrens Hospital Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | - |
| Primary Children's Medical Center | Salt Lake City | Utah | 84113 | - |
Related coverage on Hipa.ai
- Inclisiran for Heterozygous Familial Hypercholesterolemia Shows Significant…Inclisiran · Jun 10, 2025 · ClinicalTrials.gov
Find similar trials in Tucson, AZ
By research site
Tucson Medical Center· Tucson, AZIcahn School of Medicine at Mount Sinai· New York, NYWake Forest U of Health Sciences· Winston-Salem, NCCincinnati Children's Hospital Medical Center· Cincinnati, OHChildrens Hospital Pittsburgh of UPMC· Pittsburgh, PAPrimary Children's Medical Center· Salt Lake City, UT
Related Studies
- Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaPHASE3 · Recruiting · Novartis Pharmaceuticals · San Francisco, California
- Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHPHASE3 · Not Yet Recruiting · LIB Therapeutics LLC · Cincinnati, Ohio